SAN DIEGO–(BUSINESS WIRE)–Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced the addition of Xiaogang Pan, PhD to its Board of Directors, and Ian Storer, PhD to its Scientific Advisory Board.
Pan Xiaogang, currently Managing Director of AstraZeneca-CICC Fund and Business Development in AstraZeneca China, leads the investment activities in innovative medicine. Xiaogang has nearly 20 years of combined experiences in research, business development and investment. Prior to joining AstraZeneca in 2015, Xiaogang worked for Amgen, Bayer, GSK and Ferring. Xiaogang holds a PhD in Pharmaceutics from The Ohio State University.
Dr. Ian Storer is currently Vice President, Head of Hit Discovery in Global Research and Development at AstraZeneca Pharmaceuticals in the UK. Prior to joining AstraZeneca, Dr Storer spent 10 years at Pfizer as a medicinal chemist and pre-clinical project leader. Before entering the pharmaceutical industry, he earned his Ph.D. in organic chemistry from the University of Cambridge with Professor Steven V. Ley, followed by postdoctoral research at Caltech working with Professor Sir David W. C. MacMillan.
Dr. Ying Luo, Cullgen’s CEO, commented, “We are very pleased to have Drs. Pan and Storer join Cullgen in these important advisory roles. Both Xiaogang and Ian have extensive experience at AstraZeneca relating to targeted protein degraders and drug development, and I look forward to their contributions to help advance our platform and portfolio of targeted protein degraders.”
About Cullgen Inc.:
Cullgen is a privately held clinical-stage biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. The company applies its proprietary uSMITE™ (ubiquitin-mediated, small molecule -induced target elimination) platform to expand the drug design paradigm beyond functional site inhibition, enabling the targeting of historically “undruggable” proteins for selective destruction. Leveraging years of work by its founders on the proteasome system and key discoveries regarding its functionality, Cullgen has successfully generated multiple highly potent, selective, and bioavailable targeted protein degrader compounds that utilize proprietary novel E3 ligands. For more information, visit www.cullgen.com.
Contacts
Cullgen Inc.
Thomas Eastling, CFO
inquiries@cullgen.com